Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 3 (February 1), 2004: pp. 560-562
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.03.060

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakajima, H.
Right arrow Articles by Ando, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakajima, H.
Right arrow Articles by Ando, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

DIAGNOSIS IN ONCOLOGY

Unusual Lymphoma Manifestations

CASE 3. CD8+ T-Cell Prolymphocytic Leukemia

Hikaru Nakajima, Masayuki Oki, Kiyoshi Ando

Division of Hematology/Medical Oncology, Departments of Medicine Tokai University School of Medicine, Isehara, Japan

A 33-year-old Japanese woman was referred because of leukocytosis with increased abnormal lymphocytes on a routine blood test. She was completely asymptomatic. Physical examination was essentially normal with no lymphadenopathy, hepatosplenomegaly, or skin lesions. CBC showed WBC 24.5 x 109/L with segmented neutrophils 10%, lymphocytes 5%, monocytes 2%, eosinophils 1%, basophils 1%, abnormal lymphocytes 81%, hemoglobin 12.0 g/dL, and platelets 210 x 109/L. Blood chemistry including lactate dehydrogenase and calcium were normal. Immunoglobin M was slightly elevated at 360 mg/dL, but other immunoglobulin classes were normal. Serum protein electrophoresis showed no monoclonal protein. Her hepatitis serology, including hepatitis B antigen and hepatitis C antibodies, was negative. Human T-cell lymphotropic virus-1 and HIV antibodies were also negative. Peripheral blood smear (Fig 1) showed abnormal lymphocytes that were small and had indented and irregular nuclei with condensed chromatin and no apparent nucleolus. Cytoplasm was basophilic and lacked granulations. Bone marrow was hypercellular with diffuse infiltration by these same abnormal lymphocytes (Fig 2). Immunophenotype analysis (Fig 3) of peripheral blood revealed the abnormal lymphocytes were CD1-, CD2+, CD3+, CD4-, CD5+, CD7+, CD8+, CD10-, CD16-, CD19-, CD20-, CD22-, CD23-, CD25-, CD30-, CD34-, CD38dim+, CD45+, CD56-, CD57-, sIg-, TCR{alpha}ß+, TCR{delta}{gamma}-, and TdT-. Southern blot analysis for TCR-Cß1 showed rearranged bands, suggesting a clonal process of disease (Fig 4). No metaphase cells for cytogenetic analysis were obtained in unstimulated culture of peripheral blood. Cytogenetic study with phytohemagglutinin stimulation showed 42, X, -X, add(6)(p25), add(7)(q36), I(8)(q10), -11, add(12)(p13), +13, -14, -15, -15, -17, add(19)(q13.4), add(20)(q13.3), -22, +mar2 in all nine cells analyzed (Fig 5). A diagnosis of CD8+ T-cell prolymphocytic leukemia (T-PLL) was made. She developed progressive abnormal lymphocytosis, liver function test abnormalities, cervical lymphadenopathy, and erythematous skin lesions 3 months after diagnosis. She was treated with two courses of deoxycoformycin without any response. Therapy was changed to cyclophosphamide, doxorubicin, vincristine, and prednisone, resulting in resolution of liver function test abnormalities, decreased lymphadenopathy, and stable peripheral abnormal lymphocyte counts. She is awaiting an unrelated allogeneic bone marrow transplantation.



View larger version (102K):
[in this window]
[in a new window]
 
Fig 1.

 


View larger version (130K):
[in this window]
[in a new window]
 
Fig 2.

 


View larger version (26K):
[in this window]
[in a new window]
 
Fig 3.

 


View larger version (132K):
[in this window]
[in a new window]
 
Fig 4.

 


View larger version (112K):
[in this window]
[in a new window]
 
Fig 5.

 
The differential diagnosis of increased abnormal T cells in the peripheral blood includes adult T-cell leukemia (ATL), leukemic phase of cutaneous T-cell lymphoma, large granular lymphocyte (T-LGL) leukemia and T-PLL. ATL was ruled out because of the negative serology for human T-cell lymphotropic virus-1 and the fact that most ATL are CD4+ CD8-. Cutaneous T-cell lymphoma was highly unlikely because of absence preceding cutaneous lesions. CD3+ T-LGL leukemia is ruled out by lack of increased large granular lymphocytes with CD16+ CD57+ phenotype [1]. Additionally, patients with CD3+ T-LGL leukemia present with neutropenia, anemia, and splenomegaly.

A new variant of T-cell chronic lymphocytic leukemia with CD8+ phenotype was described in 1987 [2]. T-cell chronic lymphocytic leukemia is now reclassified as T-PLL according to the WHO/revised form of European-American Classification of lymphoid neoplasms classification for lymphoid malignancies because of aggressive clinical behavior [3]. It represents approximately 30% of T-cell leukemias with a mature phenotype. Clinical features of T-PLL include occurrence in older patients, hepatosplenomegaly, lymphadenopathy, skin lesions, leukocytosis, anemia, and thrombocytopenia [4]. The majority of cases are CD4+ CD8-; however, approximately 10% of T-PLL are CD4- CD8+ [4,5]. Although no pathognomonic cytogenetic abnormalities have been identified, many cases show abnormalities involving chromosome 14 at bands q11 and q32 [4-8]. The clinical course is aggressive and tends to be resistant to chemotherapy. Median survival is approximately 1 year. Our case fulfills the clinical, morphologic, and immunophynotypic criteria for CD8+ T-PLL with unusual cytogenetic abnormalities. It is important to recognize T-PLL because it has a more aggressive clinical course than mature T-cell leukemias.

Authors’ Disclosures of Potential Conflicts of Interest

The authors indicated no potential conflicts of interest.

REFERENCES

1. Loughran TP Jr: Clonal diseases of large granular lymphocytes. Blood 82: 1-14, 1993[Abstract/Free Full Text]

2. Hui PK, Feller AC, Pileri S, et al: New aggressive variant of suppressor/cytotoxic T-CLL. Am J Clin Pathol 87: 55-59, 1987[Medline]

3. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84: 1361-1392, 1994[Free Full Text]

4. Matutes E, Brito-Babapulle V, Swansbury J, et al: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78: 3269-3274, 1991[Abstract/Free Full Text]

5. Matutes E, Catovsky D: Mature T-cell leukemias and leukemia/lymphoma syndromes. Review of our experience in 175 cases. Leuk Lymphoma 4: 81-91, 1991

6. Heinonen K, Mahlamaki E, Hamalainen E, et al: Multiple karyotypic abnormalities in three cases of small cell variant of T-cell prolymphocytic leukemia. Cancer Genet Cytogenet 78: 28-35, 1994[Medline]

7. Brito-Babapulle V, Maljaie SH, Matutes E, et al: Relationship of T leukaemias with cerebriform nuclei to T-prolymphocytic leukaemia: A cytogenetic analysis with in situ hybridization. Br J Haematol 96: 724-732, 1997[CrossRef][Medline]

8. Brito-Babapulle V, Pomfret M, Matutes E, et al: Cytogenetic studies on prolymphocytic leukemia. II. T cell prolymphocytic leukemia Blood 70: 926-931, 1987


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakajima, H.
Right arrow Articles by Ando, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakajima, H.
Right arrow Articles by Ando, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online